List of Tables
Table 1. Global Anti-VEGF Ophthalmic Drugs Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Anti-VEGF Ophthalmic Drugs Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Anti-VEGF Ophthalmic Drugs Market Competitive Situation by Manufacturers in 2025
Table 4. Global Anti-VEGF Ophthalmic Drugs Sales (K Dose) of Key Manufacturers (2021–2026)
Table 5. Global Anti-VEGF Ophthalmic Drugs Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Anti-VEGF Ophthalmic Drugs Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Anti-VEGF Ophthalmic Drugs Average Price (US$/Dose) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Anti-VEGF Ophthalmic Drugs, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Anti-VEGF Ophthalmic Drugs, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Anti-VEGF Ophthalmic Drugs, Product Types and Applications
Table 12. Global Key Manufacturers of Anti-VEGF Ophthalmic Drugs, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Anti-VEGF Ophthalmic Drugs Companies by Tier (Tier 1, Tier 2, Tier 3), based on Anti-VEGF Ophthalmic Drugs Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Anti-VEGF Ophthalmic Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Anti-VEGF Ophthalmic Drugs Sales by Region (K Dose), 2021–2026
Table 18. Global Anti-VEGF Ophthalmic Drugs Sales Market Share by Region (2021–2026)
Table 19. Global Anti-VEGF Ophthalmic Drugs Sales by Region (K Dose), 2027–2032
Table 20. Global Anti-VEGF Ophthalmic Drugs Sales Market Share by Region (2027–2032)
Table 21. Global Anti-VEGF Ophthalmic Drugs Revenue by Region (US$ Million), 2021–2026
Table 22. Global Anti-VEGF Ophthalmic Drugs Revenue Market Share by Region (2021–2026)
Table 23. Global Anti-VEGF Ophthalmic Drugs Revenue by Region (US$ Million), 2027–2032
Table 24. Global Anti-VEGF Ophthalmic Drugs Revenue Market Share by Region (2027–2032)
Table 25. North America Anti-VEGF Ophthalmic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Anti-VEGF Ophthalmic Drugs Sales by Country (K Dose), 2021–2026
Table 27. North America Anti-VEGF Ophthalmic Drugs Sales by Country (K Dose), 2027–2032
Table 28. North America Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2021–2026
Table 29. North America Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Anti-VEGF Ophthalmic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Anti-VEGF Ophthalmic Drugs Sales by Country (K Dose), 2021–2026
Table 32. Europe Anti-VEGF Ophthalmic Drugs Sales by Country (K Dose), 2027–2032
Table 33. Europe Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Anti-VEGF Ophthalmic Drugs Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Anti-VEGF Ophthalmic Drugs Sales by Region (K Dose), 2021–2026
Table 37. Asia Pacific Anti-VEGF Ophthalmic Drugs Sales by Region (K Dose), 2027–2032
Table 38. Asia Pacific Anti-VEGF Ophthalmic Drugs Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Anti-VEGF Ophthalmic Drugs Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Anti-VEGF Ophthalmic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Anti-VEGF Ophthalmic Drugs Sales by Country (K Dose), 2021–2026
Table 42. Latin America Anti-VEGF Ophthalmic Drugs Sales by Country (K Dose), 2027–2032
Table 43. Latin America Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Anti-VEGF Ophthalmic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Anti-VEGF Ophthalmic Drugs Sales by Country (K Dose), 2021–2026
Table 47. Middle East and Africa Anti-VEGF Ophthalmic Drugs Sales by Country (K Dose), 2027–2032
Table 48. Middle East and Africa Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2027–2032
Table 50. Global Anti-VEGF Ophthalmic Drugs Sales (K Dose) by Type (2021–2026)
Table 51. Global Anti-VEGF Ophthalmic Drugs Sales (K Dose) by Type (2027–2032)
Table 52. Global Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2021–2026)
Table 53. Global Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2027–2032)
Table 54. Global Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Anti-VEGF Ophthalmic Drugs Revenue Market Share by Type (2021–2026)
Table 57. Global Anti-VEGF Ophthalmic Drugs Revenue Market Share by Type (2027–2032)
Table 58. Global Anti-VEGF Ophthalmic Drugs Price (US$/Dose) by Type (2021–2026)
Table 59. Global Anti-VEGF Ophthalmic Drugs Price (US$/Dose) by Type (2027–2032)
Table 60. Global Anti-VEGF Ophthalmic Drugs Sales (K Dose) by Application (2021–2026)
Table 61. Global Anti-VEGF Ophthalmic Drugs Sales (K Dose) by Application (2027–2032)
Table 62. Global Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2021–2026)
Table 63. Global Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2027–2032)
Table 64. Global Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Anti-VEGF Ophthalmic Drugs Revenue Market Share by Application (2021–2026)
Table 67. Global Anti-VEGF Ophthalmic Drugs Revenue Market Share by Application (2027–2032)
Table 68. Global Anti-VEGF Ophthalmic Drugs Price (US$/Dose) by Application (2021–2026)
Table 69. Global Anti-VEGF Ophthalmic Drugs Price (US$/Dose) by Application (2027–2032)
Table 70. Roche Company Information
Table 71. Roche Description and Business Overview
Table 72. Roche Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 73. Roche Anti-VEGF Ophthalmic Drugs Product
Table 74. Roche Recent Developments/Updates
Table 75. Novartis Company Information
Table 76. Novartis Description and Business Overview
Table 77. Novartis Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 78. Novartis Anti-VEGF Ophthalmic Drugs Product
Table 79. Novartis Recent Developments/Updates
Table 80. Coherus BioSciences Company Information
Table 81. Coherus BioSciences Description and Business Overview
Table 82. Coherus BioSciences Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 83. Coherus BioSciences Anti-VEGF Ophthalmic Drugs Product
Table 84. Coherus BioSciences Recent Developments/Updates
Table 85. Regeneron Pharmaceuticals Company Information
Table 86. Regeneron Pharmaceuticals Description and Business Overview
Table 87. Regeneron Pharmaceuticals Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 88. Regeneron Pharmaceuticals Anti-VEGF Ophthalmic Drugs Product
Table 89. Regeneron Pharmaceuticals Recent Developments/Updates
Table 90. Samsung Bioepis Company Information
Table 91. Samsung Bioepis Description and Business Overview
Table 92. Samsung Bioepis Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 93. Samsung Bioepis Anti-VEGF Ophthalmic Drugs Product
Table 94. Samsung Bioepis Recent Developments/Updates
Table 95. Biocon Biologics Company Information
Table 96. Biocon Biologics Description and Business Overview
Table 97. Biocon Biologics Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 98. Biocon Biologics Anti-VEGF Ophthalmic Drugs Product
Table 99. Biocon Biologics Recent Developments/Updates
Table 100. Chengdu Kanghong Pharmaceutical Company Information
Table 101. Chengdu Kanghong Pharmaceutical Description and Business Overview
Table 102. Chengdu Kanghong Pharmaceutical Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 103. Chengdu Kanghong Pharmaceutical Anti-VEGF Ophthalmic Drugs Product
Table 104. Chengdu Kanghong Pharmaceutical Recent Developments/Updates
Table 105. Key Raw Materials Lists
Table 106. Raw Materials Key Suppliers Lists
Table 107. Anti-VEGF Ophthalmic Drugs Distributors List
Table 108. Anti-VEGF Ophthalmic Drugs Customers List
Table 109. Anti-VEGF Ophthalmic Drugs Market Trends
Table 110. Anti-VEGF Ophthalmic Drugs Market Drivers
Table 111. Anti-VEGF Ophthalmic Drugs Market Challenges
Table 112. Anti-VEGF Ophthalmic Drugs Market Restraints
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
Table 116. Authors List of This Report
List of Figures
Figure 1. Product Picture of Anti-VEGF Ophthalmic Drugs
Figure 2. Global Anti-VEGF Ophthalmic Drugs Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Anti-VEGF Ophthalmic Drugs Market Share by Type: 2025 & 2032
Figure 4. Monoclonal Antibodies Product Picture
Figure 5. Fusion Proteins Product Picture
Figure 6. Global Anti-VEGF Ophthalmic Drugs Market Value by Application (US$ Million), 2021–2032
Figure 7. Global Anti-VEGF Ophthalmic Drugs Market Share by Application: 2025 & 2032
Figure 8. Age-related Macular Degeneration
Figure 9. Diabetic Retinopathy
Figure 10. Other
Figure 11. Global Anti-VEGF Ophthalmic Drugs Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 12. Global Anti-VEGF Ophthalmic Drugs Market Size (US$ Million), 2021–2032
Figure 13. Global Anti-VEGF Ophthalmic Drugs Sales (K Dose), 2021–2032
Figure 14. Global Anti-VEGF Ophthalmic Drugs Average Price (US$/Dose), 2021–2032
Figure 15. Anti-VEGF Ophthalmic Drugs Report Years Considered
Figure 16. Anti-VEGF Ophthalmic Drugs Sales Share by Manufacturers in 2025
Figure 17. Global Anti-VEGF Ophthalmic Drugs Revenue Share by Manufacturers in 2025
Figure 18. Top 5 and Top 10 Global Anti-VEGF Ophthalmic Drugs Players: Market Share by Revenue in Anti-VEGF Ophthalmic Drugs in 2025
Figure 19. Anti-VEGF Ophthalmic Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 20. Global Anti-VEGF Ophthalmic Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 21. North America Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2021–2032)
Figure 22. North America Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2021–2032)
Figure 23. United States Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 24. Canada Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Europe Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2021–2032)
Figure 26. Europe Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2021–2032)
Figure 27. Germany Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. France Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. U.K. Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Italy Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Russia Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Asia Pacific Anti-VEGF Ophthalmic Drugs Sales Market Share by Region (2021–2032)
Figure 33. Asia Pacific Anti-VEGF Ophthalmic Drugs Revenue Market Share by Region (2021–2032)
Figure 34. China Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Japan Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. South Korea Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. India Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Australia Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. China Taiwan Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Southeast Asia Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Latin America Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2021–2032)
Figure 42. Latin America Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2021–2032)
Figure 43. Mexico Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Brazil Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Argentina Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Colombia Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Middle East and Africa Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2021–2032)
Figure 48. Middle East and Africa Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2021–2032)
Figure 49. Turkey Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Saudi Arabia Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. UAE Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Global Sales Market Share of Anti-VEGF Ophthalmic Drugs by Type (2021–2032)
Figure 53. Global Revenue Market Share of Anti-VEGF Ophthalmic Drugs by Type (2021–2032)
Figure 54. Global Anti-VEGF Ophthalmic Drugs Price (US$/Dose) by Type (2021–2032)
Figure 55. Global Sales Market Share of Anti-VEGF Ophthalmic Drugs by Application (2021–2032)
Figure 56. Global Revenue Market Share of Anti-VEGF Ophthalmic Drugs by Application (2021–2032)
Figure 57. Global Anti-VEGF Ophthalmic Drugs Price (US$/Dose) by Application (2021–2032)
Figure 58. Anti-VEGF Ophthalmic Drugs Value Chain
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
